Is amyloid-β harmful to the brain? Insights from human imaging studies.

  title={Is amyloid-$\beta$ harmful to the brain? Insights from human imaging studies.},
  author={William J. Jagust},
  journal={Brain : a journal of neurology},
  volume={139 Pt 1},
  • W. Jagust
  • Published 2016
  • Psychology, Biology
  • Brain : a journal of neurology
Although the amyloid-β protein associated with the Alzheimer's disease plaque has been detectable in living people for over a decade, its importance in the pathogenesis of Alzheimer's disease is still debated. The frequent presence of amyloid-β in the brains of cognitively healthy older people has been interpreted as evidence against a causative role. If amyloid-β is crucial to the development of Alzheimer's disease, it should be associated with other Alzheimer's disease-like neurological… 

Figures from this paper

Amyloid biomarkers: pushing the limits of early detection.
It is provided compelling evidence that CSF amyloid-β1-42 may be more sensitive than amyloids PET to the early stages ofAmyloid deposition (Palmqvist et al. , 2016), a finding that has important ramifications for the understanding of preclinical Alzheimer’s disease and for the design of prevention trials.
EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease.
Early biomarkers are needed to identify individuals at high risk of preclinical Alzheimer's disease and to better understand the pathophysiological processes of disease progression. Preclinical
Joint associations of β-amyloidosis and cortical thickness with cognition
β-Amyloid accumulation in the human brain after one night of sleep deprivation
The findings show adverse effects of one-night sleep deprivation on brain ABB and expand on prior findings of higher Aβ accumulation with chronic less sleep.
Update on biomarkers for amyloid pathology in Alzheimer's disease.
The current clinical, diagnostic and research state of biomarkers for A β pathology is discussed and the current application of blood-based markers to assess Aβ pathology is explored.
Recent advances in cerebrospinal fluid biomarkers for the detection of preclinical Alzheimer's disease.
Further longitudinal research is necessary to delineate the temporal changes of core and candidate CSF biomarkers in preclinical Alzheimer's disease and to investigate their association with established and emerging neuroimaging markers as well as with comorbidities and other risk factors for age-related cognitive decline.
Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities
It is demonstrated that amyloid-β pathology recapitulates an Alzheimer-like profile of biomarker abnormalities even in the absence of other hallmarks of the disease such as neurofibrillary tangles and widespread neuronal losses.
Visual and Ocular Manifestations of Alzheimer’s Disease and Their Use as Biomarkers for Diagnosis and Progression
The evidence surrounding ocular changes in AD is explored and the biomarkers currently in development for early diagnosis are considered, which may enable earlier diagnosis in the clinical setting, minimizing invasive and expensive investigations.


Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
In the pre-dementia stage of Alzheimer's disease, subtle episodic memory impairment is related to β-amyloid deposition, especially in the temporal neocortex, and independently from hippocampal atrophy, suggesting that both factors should be independently targeted in therapeutic trials aimed at reducing cognitive decline.
Atrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials
It is concluded that hippocampal atrophy may be a feasible outcome measure for secondary prevention studies in asymptomatic amyloidosis, and recruiting 384 amyloids-positive subjects/arm will provide 80% power to detect 25% absolute slowing of hippocampa atrophy rate in an 18-month treatment trial.
Alzheimer's Disease Neurodegenerative Biomarkers Are Associated with Decreased Cognitive Function but Not β-Amyloid in Cognitively Normal Older Individuals
The findings indicate that neurodegeneration occurs within AD regions regardless of Aβ deposition and accounts for worse cognition in cognitively normal older people and the impact of neural integrity on cognitive functions is enhanced in the presence of high Aβ burden for brain regions that are most affected in AD.
Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis.
Higher rates of medial temporal neurodegeneration occur in CN individuals who, on their initial scans, had abnormal levels of both β-amyloid and brain injury biomarkers, which is critical for trials designed to prevent or forestall dementia due to AD.
The case for rejecting the amyloid cascade hypothesis
The proposition that the authors are over-reliant on amyloid to define and diagnose AD is explored and that the time has come to face their fears and reject the amyloids cascade hypothesis.
Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
The combined detection of amyloid positivity and objectively-defined decline in memory are reliable indicators of early Alzheimer's disease, and the detection of decline in non-memory functions in amyloids-positive individuals with mild cognitive impairment may assist in determining the level of disease severity in these individuals.
Amyloid burden and neural function in people at risk for Alzheimer's Disease
Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition
The findings show that the presence of Aβ in the brain, known to occur in about one-third of asymptomatic elderly individuals, is actually a pathologic state associated with accelerated atrophy, and suggest that therapy aimed to reduce the neurodegenerative process should be commenced in presymPTomatic individuals with high PiB.